Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2423studies indexed1086with human data145registered trials2091carry a numeric findingLibrarian added 0 studies today
Showing 8 studiesSortNewest indexed ▾
A
grade
Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
B7-33 (Relaxin) · Lancet (London, England) · 2009 · RCTTop journal
Relaxin may improve dyspnoea and reduce hospital stay in patients with acute heart failure, but further studies are needed to confirm these findings.
40% of patients in the relaxin 30 microg/kg group moderately or markedly improved dyspnoea at 6 h, 12 h, and 24 h vs 23% in the placebo group, p=0.044.
B
grade
Heterozygous germline <i>MSH3</i> mutations, and probably <i>MLH3</i> mutations, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk
B7-33 (Relaxin) · biorxiv-preprint · 2026 · Observational
Heterozygous germline mutations in MSH3 and MLH3 are associated with increased colorectal cancer risk, suggesting they may be included in genetic screening for CRC.
2.2-fold increased risk of CRC for heterozygous MSH3 mutations, P=6.6x10^-5
B
grade
A relative methylation ordering biomarker of lactylation-related genes predicts prognosis and therapeutic response in cutaneous melanoma.
B7-33 (Relaxin) · Epigenetics · 2026 · Observational · n=699
This study indicates that lactylation-related methylation patterns may help stratify cutaneous melanoma patients into high- and low-risk groups, potentially informing treatment strategies.
Kaplan-Meier log-rank test, p=0.046 for survival differences between clusters.
A
grade
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
B7-33 (Relaxin) · Oncoimmunology · 2026 · Observational · Phase 2 · n=130
Combining chemotherapy with immunotherapy may improve survival in some patients with microsatellite stable metastatic colorectal cancer, but the benefits may vary based on individual patient characteristics.
Median OS not reached vs 15.3 months; HR=0.58; 95% CI, 0.36-0.96; p=0.03.
Showing 8 of 8